TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$400 Million

Celldex Therapeutics, Inc.

Follow-on Offering

Bookrunner, February 2024

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. (“Celldex” or “The Company”) (NASDAQ: CLDX) is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Celldex’s pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases.